Other monogenic epilepsies for which a molecular diagnosis may influence the choice of anti-epileptic drugs are KCNQ2-related epilepsies and the use of ezogabine [83, 84], SCN1A-related Dravet syndrome and the use of clemizole [85], and DEPDC5 and the use of the rapamycin derivative everolimus, which has already been effective in early clinical trials [86]. The gene discussed is SCN1A; the disease is Dravet syndrome.